



PMI RESEARCH & DEVELOPMENT

Study ZRHM-REXA-07-JP Clinical Study Report Signature Pages

Study Title: A randomized, controlled, open-label, 3-arm parallel group, multi-center study to demonstrate reductions in exposure to selected smoke constituents in healthy smokers switching to the Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol) or observing smoking abstinence, compared to continuing to use menthol conventional cigarettes, for 5 days in confinement and prolonged by 85 days in an ambulatory setting

Study Number: ZRHM-REXA-07-JP

Product Name: Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol)

Principal Investigator and Affiliation: Mamoru Oki, MD, PhD
Seishukai Clinic 3-18-5, Matsugaya, Taitou-ku
Tokyo 111-0036, Japan
Professor Masahiro Endo, MD
Tokyo Heart Center Osaki Hospital,
5-4-12, Kitashinagawa,
Shinagawa ku,
Tokyo 141-0001, Japan

Sponsor: Philip Morris Products S.A.
PMI Research & Development
Quai Jeanrenaud 5
2000 Neuchâtel, Switzerland

Sponsor Signatories: Christelle Haziza, PhD, Manager P1 Clinical Program, Clinical Scientist
Nicola Lama, PhD, Biostatistician
Andrea Donelli, Clinical Scientist
Patrick Picavet, MD, Medical Safety Officer

Version: 1.0

Date: 24 February 2016

Confidentiality Statement

This document is confidential. Disclosure of any of its contents to third parties is not permitted except by the prior written consent of Philip Morris Products S.A.



PRINCIPAL INVESTIGATOR'S SIGNATURE

PRINCIPAL INVESTIGATOR'S SIGNATURE

Study Title: A randomized, controlled, open-label, 3-arm parallel group, multi-center study to demonstrate reductions in exposure to selected smoke constituents in healthy smokers switching to the Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol) or observing smoking abstinence, compared to continuing to use menthol conventional cigarettes, for 5 days in confinement and prolonged by 85 days in an ambulatory setting

Study Number: ZRHM-REXA-07-JP

I have read the Clinical Study Report referenced above and confirm that to the best of my knowledge it accurately describes the conduct and results of the study.

Signed: Masahiro Endo
Professor Masahiro Endo, MD

Date: 02 MAR 2016



PRINCIPAL INVESTIGATOR'S SIGNATURE

PRINCIPAL INVESTIGATOR'S SIGNATURE

Study Title: A randomized, controlled, open-label, 3-arm parallel group, multi-center study to demonstrate reductions in exposure to selected smoke constituents in healthy smokers switching to the Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol) or observing smoking abstinence, compared to continuing to use menthol conventional cigarettes, for 5 days in confinement and prolonged by 85 days in an ambulatory setting

Study Number: ZRHM-REXA-07-JP

I have read the Clinical Study Report referenced above and confirm that to the best of my knowledge it accurately describes the conduct and results of the study.

Signed: Mamoru Oki
Mamoru Oki, MD

Date: 8 May 2016

**SIGNATURES OF SPONSORS RESPONSIBLE PERSONNEL**

This Clinical Study Report was subject to critical review and has been approved by the Sponsor.


SPONSOR SIGNATORIES**Study Title:**

A randomized, controlled, open-label, 3-arm parallel group, multi-center study to demonstrate reductions in exposure to selected smoke constituents in healthy smokers switching to the Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol) or observing smoking abstinence, compared to continuing to use menthol conventional cigarettes, for 5 days in confinement and prolonged by 85 days in an ambulatory setting


Study Number:

ZRHM-REXA-07-JP

We, the undersigned, confirm that to the best of our knowledge this clinical study report accurately describes the experimental methods and results of the study.

Signed: 
Christelle Haziza, PhD
Manager P1 Clinical Program, Clinical Scientist

Date: 02 March 2016

Signed: 
Nicola Lama, PhD
Biostatistician

Date: 07 MARCH 2016

Signed: 
Andrea Donelli
Clinical Scientist

Date: 07 MARCH 2016

Signed: 
Patrick Picavet, MD
Medical Safety Officer

Date: 02 MARCH 2016